7 recruiting, 3 not yet recruiting, 3 terminated, 1 completed. 14 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Recruiting 7, Not yet recruiting 3, Terminated 3, Completed 1 |
| Phase 2 | 5 | Not yet recruiting 2, Recruiting 2, Completed 1 |
Follow RAS Mutation: new trials by email Literature Review of RAS Mutation trials Research Report on RAS Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation. GFH276, with or without Tislelizumab, Pemetrexed - RAS Mutation, Non-small Cell Lung Cancer (NSCLC) | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 84 | 2026-11-01 | 2026-09-29 |
| TNG462-C103: Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Vopimetostat in Combination With ERAS-0015 in PDAC and NSCLC Patients vopimetostat, ERAS-0015 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Tango Therapeutics, Inc. | 188 | 2026-11-01 | 2026-10-27 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations ASKC189 - Solid Tumor, RAS Mutation | Phase 1 | Not yet recruiting | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | 200 | 2026-09-30 | 2026-09-23 |
| A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression Intravenous AN4035, Intravenous AN4035 followed by intravenous EGFR Inhibitor. - Solid Tumor (Phase I), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 228 | 2026-09-23 | 2026-10-16 |
| A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations BG-85738, Tislelizumab, Cetuximab - RAS Mutation, Advanced Solid Tumor | Phase 1 | Recruiting | BeOne Medicines | 100 | 2026-09-02 | 2026-10-23 |
| A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation GFH276, Cetuximab, Nab paclitaxel - Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 222 | 2026-09-01 | 2026-10-05 |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations AN9025 oral capsule - Solid Tumors (Phase 1), RAS Mutation | Phase 1 | Recruiting | Adlai Nortye Biopharma Co., Ltd. | 118 | 2026-01-28 | 2026-06-08 |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients TNG462, RMC-9805, RMC-6236 - PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 183 | 2025-05-31 | 2026-10-23 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| PAS-004 in Patients With Advanced Solid Tumors PAS-004 Capsules, PAS-004 Tablets - RAS Mutation, NF1 Mutation | Phase 1 | Recruiting | Pasithea Therapeutics Corp. | 83 | 2024-02-29 | 2026-10-30 |
| Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors. ABM-168 - Advanced Solid Tumor, RAS Mutation | Phase 1 | Terminated | ABM Therapeutics Corporation | 12 | 2023-03-30 | 2024-12-06 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) OKI-179 + binimetinib - RAS Mutation, NRAS Gene Mutation | Phase 1 / Phase 2 | Completed | OnKure, Inc. | 36 | 2022-05-11 | 2025-03-07 |
| Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors Tovorafenib, Tovorafenib Drug: Pimasertib - Melanoma, Solid Tumor | Phase 1 | Terminated | Day One Biopharmaceuticals, Inc. | 44 | 2022-05-02 | 2025-08-14 |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies RSC-1255 Dose Escalation, RSC-1255 Dose Expansion - Advanced Malignant Solid Neoplasm, RAS Mutation | Phase 1 | Recruiting | RasCal Therapeutics, Inc. | 134 | 2021-03-03 | 2026-06-23 |
Lung Neoplasms (4) · Melanoma (4) · Carcinoma, Non-Small-Cell Lung (3) · Pancreatic Neoplasms (3) · Colorectal Neoplasms (2) · Glioblastoma (2) · Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Colonic Neoplasms (1) · Disease Progression (1) · Neoplasm Metastasis (1)
Neoplasms (8) · Neoplasms by Site (8) · Lung Diseases (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (5) · Neoplasms, Nerve Tissue (5) · Neuroectodermal Tumors (5) · Neuroendocrine Tumors (4) · Nevi and Melanomas (4) · Skin Diseases (4) · Skin Neoplasms (4) · Skin and Connective Tissue Diseases (4)
Cetuximab (2) · tislelizumab (2) · Carboplatin (1) · Cisplatin (1) · Fluorouracil (1) · Gemcitabine (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Pemetrexed (1) · Taxes (1) · binimetinib (1) · tovorafenib (1)
Adlai Nortye Biopharma Co., Ltd. (2) · Genfleet Therapeutics (Shanghai) Inc. (2) · Tango Therapeutics, Inc. (2) · ABM Therapeutics Corporation (1) · BeOne Medicines (1) · Day One Biopharmaceuticals, Inc. (1) · Deciphera Pharmaceuticals, LLC (1) · Jiangsu Aosaikang Pharmaceutical Co., Ltd. (1) · OnKure, Inc. (1) · Pasithea Therapeutics Corp. (1) · RasCal Therapeutics, Inc. (1)
United States (8) · Australia (3) · China (2) · Bulgaria (1) · Canada (1) · New Zealand (1) · Romania (1)
Kartik Krishnan, MD, PhD (1) · Maxim Pimpkin, MD, PhD (1) · Michael Mann, MD (1) · Ryan Sullivan, MD (1) · Ziming Li, MD (1)